The biopharmaceutical company Pharnext was founded in April 2007 by Professor Daniel Cohen and his main collaborators. Pharnext's mission is to discover and develop new therapeutic solutions (PleodrugsTM) and companion tests for unmet medical needs by using the PleotherapyTM approach.

We are pleased to announce a €2.5 million round of financing. Parinvest, Jean-Charles Naouri's holding company, invests in Pharnext.